Report: cancer drug spend rises, metabolic scripts jump

Share this article:

Spending on cancer treatments is rising much faster than for other common pharmaceuticals, a report issued on Monday said.
Spending on cancer and related medications rose by 15 percent in 2004, nearly double the increase in 2003, according to a report from Medco Health Solutions.
Increased use of Novartis' Gleevec and AstraZeneca's Iressa accounted for most of the jump, the report said.
The report also found that Americans with metabolic syndrome account for $4 of every $10 spent on prescription drugs for adults.
Annual prescription costs for people 20 and older with metabolic syndrome averaged $4,116 last year, 4.2 times the average amount spent on drugs for that age group, the Medco
report said.
Adult use of medication for metabolic syndrome -- a condition marked by excess abdominal fat, diabetes, high blood pressure and cholesterol problems -- jumped 36 percent between 2002 and 2004.
Medco reached its findings by examining prescription records from a random sample of 2 million clients.

 

Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.